Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology-Oncology Fellowship, Duke University School of Medicine 2015 - 2018
  • Internal Medicine Residency, University of Maryland School of Medicine 2012 - 2015
  • M.D., Jefferson Medical College of Thomas Jefferson University 2012
• Research
• 

  Selected Grants

  • Cancer cell intrinsic and extrinsic actions of steroid hormones in breast tumors awarded by Department of Defense 2018 - 2022
  • Phase II Multicenter Study of Durvalumab (MEDI4736) and Olaparib in PlatinumTreated Advanced Triple Negative Breast Cancer ¿ DORA awarded by Duke University 2018 - 2020
  • Determining the clinical efficacy and predictive biomarkers of mirvetuximab soravtansine (IMGN853) in folate receptor alpha (FRA) expressing, chemotherapy refractory triple negative breast cance awarded by National Comprehensive Cancer Network 2016 - 2019
  • TNBC Study awarded by AstraZeneca AB 2017 - 2018
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Sambade, Maria J., Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, et al. “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases..” Breast Cancer Res Treat, April 23, 2019. https://doi.org/10.1007/s10549-019-05211-1.
       Full Text  Link to Item
    • Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Targeted Oncology 14, no. 1 (February 2019): 1–12. https://doi.org/10.1007/s11523-018-0587-9.
       Full Text
    • Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Targeted Oncology 14, no. 1 (February 2019). https://doi.org/10.1007/s11523-018-0614-x.
       Full Text
    • Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype..” Clinical Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.
       Full Text
    • Narloch, Jessica L., S Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, et al. “Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis..” Neuro Oncology 19, no. 10 (October 2017): 1391–97. https://doi.org/10.1093/neuonc/nox090.
       Full Text
    • Sammons, Sarah L., Donna L. Topping, and Kimberly L. Blackwell. “HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles..” Current Cancer Drug Targets 17, no. 7 (January 2017): 637–49. https://doi.org/10.2174/1568009617666170330120452.
       Full Text

  • Book Sections

    • Sammons, S., M. McNamara, A. K. S. Salama, and J. Crawford. “Immune checkpoint inhibition.” In Side Effects of Medical Cancer Therapy: Prevention and Treatment: Second Edition, 315–53, 2018. https://doi.org/10.1007/978-3-319-70253-7_12.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.